ADAR1 Capital Management’s BridgeBio Pharma BBIO Stock Holding History

ADAR1 Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7M	Sell	94,292 -119,122	-56%	-$8.63M	0.41%	59
2025 Q4	$16.3M	Sell	213,414 -60,000	-22%	-$3.94M	1.2%	17
2025 Q3	$14.2M	Buy	273,414 +13,755	+5%	+$671K	1.33%	14
2025 Q2	$11.2M	Sell	259,659 -79,976	-24%	-$2.91M	1.72%	13
2025 Q1	$11.7M	Sell	339,635 -339,222	-50%	-$11.4M	2.18%	10
2024 Q4	$18.6M	Sell	678,857 -769,613	-53%	-$19.9M	3.72%	7
2024 Q3	$36.9M	Buy	1,448,470 +183,900	+15%	+$4.83M	6%	3
2024 Q2	$32M	Buy	1,264,570 +714,766	+130%	+$19.5M	6.05%	5
2024 Q1	$17M	Buy	549,804 +364,667	+197%	+$12.4M	3.86%	10
2023 Q4	$7.47M	Buy	+185,137	New	+$5.56M	2.67%	7

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's BBIO Position: Q1 2026 in Review

ADAR1 Capital Management reduced its BridgeBio Pharma (BBIO) stake by 56% in Q1 2026, selling an estimated $8.63M and leaving 94,292 shares worth $7M. The position accounts for 0.41% of the portfolio, ranked #59.

ADAR1 Capital Management first reported a position in BBIO in Q4 2023 and has held it in 10 quarters since. The position peaked at $36.9M in Q3 2024. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

ADAR1 Capital Management held 94,292 shares of BridgeBio Pharma worth $7M as of Q1 2026.
ADAR1 Capital Management sold 119,122 BridgeBio Pharma shares in Q1 2026, an estimated $8.63M.
BridgeBio Pharma made up 0.41% of ADAR1 Capital Management's portfolio in Q1 2026, its #59 holding.
ADAR1 Capital Management first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 10 quarters since.
ADAR1 Capital Management's BridgeBio Pharma position peaked at $36.9M in Q3 2024.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.